Related Experiment Video
Updated: Mar 26, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
[Effects of NVP-BKM120 on the triple-negative breast cancer cell]
Min Zhang1, Yang Zhou1, Yunhui Hu1
1Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute and Hospital; Key Laboratory of Breast Cancer Prevention & Therapy Under Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China.
Objective:
To investigatethe effect of NVP-BKM120 on the triple-negative breast cancer cell lines.
Methods:
Breast cancer cell line MDA-MB-231 and Cal51 were divided into control group and experimental group. The inhibitory effects of BKM120 were evaluated by MTT assays. The drug effects on CSC population and characteristics were investigated through mammosphere formation assay and colony formation assay. Western blot was used to observe the expressionof related protein. The BALB/c mice were injected with stem cells (SCs) and different treatments were administered subsequently.
Results:
In MDA-MB-231 cell lines, IC50 of BKM120 was (20.01±3.46) µmol/L for SCs and (3.07±0.14) µmol/L for total cells. BKM120 significantly inhibit the cell growth, in vitrocloning and microspheres formed of triple-negative breast cancer cells. BKM120 can inhibit tumor growth in nude mice without significant adverse reactions.
Conclusion:
BKM120 can significantly inhibit the proliferation of the triple-negative breast cancer cell lines.
Insights
NVP-BKM120 effectively inhibits triple-negative breast cancer cell proliferation and tumor growth in mice. This targeted therapy shows promise for treating aggressive breast cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapy options.
- Understanding the molecular mechanisms driving TNBC growth is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the anti-cancer effects of NVP-BKM120 on triple-negative breast cancer cell lines.
- To evaluate the impact of NVP-BKM120 on cancer stem cell (CSC) populations and tumor growth in vivo.
Main Methods:
- MTT assays were used to assess the inhibitory effects of NVP-BKM120 on MDA-MB-231 and Cal51 cell lines.
- Mammosphere and colony formation assays evaluated the drug's impact on CSCs.
- Western blot analysis examined related protein expression.
- In vivo studies involved injecting stem cells into BALB/c mice and administering NVP-BKM120 treatments.
Main Results:
- NVP-BKM120 demonstrated significant inhibition of cell growth, in vitro cloning, and mammosphere formation in TNBC cells.
- The IC50 values for NVP-BKM120 in MDA-MB-231 cells were 20.01±3.46 µmol/L for SCs and 3.07±0.14 µmol/L for total cells.
- NVP-BKM120 inhibited tumor growth in nude mice without significant adverse reactions.
Conclusions:
- NVP-BKM120 significantly inhibits the proliferation of triple-negative breast cancer cell lines.
- NVP-BKM120 exhibits potential as a therapeutic agent for triple-negative breast cancer.
